Search Results
10
Everything
Search Filters
Organization
NurExone Biologic Inc
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
March 14, 2025 16:03 ET
|
NurExone Biologic Inc
ExoPTEN’s Preclinical Study Demonstrates Significant for Enhancing Motor Function, Increasing Blood Flow, and Faster Recovery After Spinal Cord Injuries
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
February 27, 2025 16:03 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been...
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
February 19, 2025 16:03 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is proud to announce its inclusion in the 2025...
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
February 14, 2025 16:03 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be...
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
February 05, 2025 16:04 ET
|
NurExone Biologic Inc
NurExone Biologic Inc. announces formation of a U.S.-based subsidiary, Exo-Top Inc. for fully characterized GMP Exosome production.
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
January 21, 2025 16:20 ET
|
NurExone Biologic Inc
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
NurExone Biologic Secures Master Cell Bank
January 08, 2025 16:12 ET
|
NurExone Biologic Inc
NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
December 06, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 27, 2024 07:01 ET
|
NurExone Biologic Inc
NurExone Reports Third Quarter 2024 Financial Results
and Provides Corporate Update
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
November 13, 2024 16:14 ET
|
NurExone Biologic Inc
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry